Paris (France), Cambridge (Massachusetts, USA), March 13, 2026 – 07:30 a.m, CET – Biophytis SA (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a pioneer in developing transformative therapies targeting longevity, announces that it participated in the Intrinsic Capacity, Frailty and Sarcopenia Research Conference for Healthy Longevity (ICFSR), held from March 10 to 12, 2026 in Washington, DC (United States).
The ICFSR international conference (https://frailty-sarcopenia.com/) is a leading international scientific event dedicated to advancing clinical research on frailty, sarcopenia and, more broadly, the mechanisms of aging. It brings together researchers, clinicians and industry stakeholders to accelerate clinical trials on frailty, sarcopenia, intrinsic capacity and healthy longevity through nutrition, exercise, geroscience and artificial intelligence.
In this context, Dr. Cendrine Tourette, Director of Clinical Programs at Biophytis, delivered an oral presentation entitled “BIO101 (20-hydroxyecdysone) in Obesity: towards Phase 2 program”, dedicated to the clinical development of BIO101 in obesity, and also participated in the Biotech Showcase, which provided an opportunity to present the latest advances in the SARA program in sarcopenia.
Biophytis’ participation in ICFSR 2026 reflects the Company’s ongoing commitment to the international scientific community to advance clinical research in age-related diseases and contribute to the development of innovative therapeutic solutions supporting healthy longevity.
